Pfizer raised its full-year profit forecast on Tuesday while reporting second-quarter results that topped Wall Street ...

In an open letter, 22 experts who designed and ran Replimmune’s Phase III IGNYTE trial answered the FDA’s issues, as outlined ...

Bristol Myers Squibb (BMS) and Bain Capital have created an independent biopharmaceutical company to develop immunology ...

Pfizer (NYSE:PFE) stock gains as the company surpasses Q2 2025 expectations with $14.7B revenue and raises its full-year ...

U.S. drugmaker Pfizer on Tuesday raised its full-year profit forecast on strong demand for its heart disease drug, Vyndaqel, ...

Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than ...

Resting-state EEG (RS-EEG) has emerged as a non-invasive, low-cost tool for Alzheimer’s disease (AD) diagnosis and ...

Bristol Myers Squibb offers a 5.6% dividend yield, strong cash flow, and AI-driven growth potential. See why I see this as a ...

Central Indiana’s radiopharmaceutical industry continues to expand rapidly, earning the state a new title from the U.S.

Prothena today reported financial results for the second quarter and first six months of 2025 and provided business highlights.

During a live event, Hans Lee, MD, and participants discussed potential approaches to modifying frontline multiple myeloma ...

The media could not be loaded, either because the server or network failed or because the format is not supported.